If participants in clinical trials mostly represent similar populations, it can be difficult to ensure treatments will be safe and effective for a broad population. This is easy to understand with age: because adolescents and children may react differently to medications or dosages, Congress passed a law that requires some FDA-approved drugs to be tested separately in adolescents and children after they are proven safe and effective for adults. In clinical trials for PTSD treatments, it is particularly important that researchers strive to include people of color and LGBTQI+ individuals, who are more likely to develop PTSD -- but less likely to receive a diagnosis or treatment. Read more: MAPS Doubles Ethnoracial Diversity in Trials Again